Measuring the Potency of a Stem Cell Therapeutic

Part of the Methods in Molecular Biology book series (MIMB, volume 1235)


The potency of a drug is one of the most important parameters of a therapeutic. Besides providing the basis for manufacturing consistency and product stability, the potency can predict product failure or toxicity due to incorrect potency, provide release criteria, and the dose that will ensure that it can be used as intended. Recently, cellular therapeutics, in particular, stem cell therapy products, have being designated as “drugs” by regulatory agencies if they produce a systemic effect in the patient. Regulatory agencies are becoming increasingly stringent with respect to the manufacture, production, and testing of these products prior to being used in a patient. A clear understanding of what potency is and how it can be measured should help erase the misunderstandings and misconceptions that have accrued within the cellular therapy field. This protocol describes how the potency of hematopoietic stem cell therapy products is determined. The same principles apply to any proliferating stem cell therapeutic product.

Key words

Potency Stem cell potency Cellular therapy Drug potency Stem cell proliferation Stem cells Umbilical cord blood Bone marrow Mobilized peripheral blood Mesenchymal stem cells 


  1. 1.
    U.S. Food and Drug Administration (FDA) (2011) Guidance for industry. Potency tests for cellular and gene therapy products.
  2. 2.
    European Medicines Agency (EMA) (2008) Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer.
  3. 3.
    U.S. Food and Drug Administration (FDA) (2009) Guidance for industry. Minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications. BloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM187144.pdf
  4. 4.
    Rich IN (2013) Potency, proliferation and engraftment potential of stem cell therapeutics: the relationship between potency and clinical outcome for hematopoietic stem cell products. J Cell Sci Ther S13:001. doi: 10.4172/2157-7013.S13-001 Google Scholar
  5. 5.
    Page KM, Zhang L, Mendizabal A et al (2011) Total colony-forming units are a strong, independent predictor or neutrophil and platelet engraftment after unrelated cord blood transplantation: a single center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant 17:1362–1374PubMedCrossRefGoogle Scholar
  6. 6.
    Hall KM, Rich IN (2011) Hematopoietic stem cell potency for cellular therapeutic transplantation. In: Pelayo R (ed) Advances in hematopoietic stem cell research. InTech, Croatia, pp 384–406Google Scholar
  7. 7.
    Rich IN (2013) The difference between stem cell viability and potency: a short guide for parents and patients. Parent’s guide to cord blood foundation.
  8. 8.
    Page KM, Zhang L, Mendizabal A (2012) The cord blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME). Transfusion 52:272–283PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Bradley TR, Metcalf D (1966) The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci 44:287–299PubMedCrossRefGoogle Scholar
  10. 10.
    Pluznik DH, Sachs J (1966) The induction of clones of normal mast cells by a substance from conditioned medium. Exp Cell Res 43:553–563PubMedCrossRefGoogle Scholar
  11. 11.
    Iscove NN, Sieber F, Winterhalter KH (1974) Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol 83:309–320PubMedCrossRefGoogle Scholar
  12. 12.
    Rich IN (2003) In vitro hematotoxicity testing in drug development: a review of past and future applications. Curr Opin Drug Discov Dev 6:100–109Google Scholar
  13. 13.
    Rich IN (2007) High-throughput in vitro hemotoxicity testing and in vitro cross-platform comparative toxicity. Expert Opin Drug Metab Toxicol 3:295–307PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.HemoGenix, IncColorado SpringsUSA

Personalised recommendations